Modality
ERT
MOA
BCMA ADC
Target
PD-1
Pathway
DDR
Parkinson'sWet AMDLGS
Development Pipeline
Preclinical
Apr 2021
→ Nov 2031
PreclinicalCurrent
NCT03490565
1,026 pts·Parkinson's
2021-04→2031-11·Not yet recruiting
NCT08570586
344 pts·Parkinson's
2025-10→2029-03·Active
1,370 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-03-042.9y awayInterim· Parkinson's
2031-11-155.6y awayInterim· Parkinson's
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2029-03-04 · 2.9y away
Parkinson's
Interim
2031-11-15 · 5.6y away
Parkinson's
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03490565 | Preclinical | Parkinson's | Not yet recr... | 1026 | EASI-75 |
| NCT08570586 | Preclinical | Parkinson's | Active | 344 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 |